NCT04174599已完成3 期
A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
EVIVE Biotechnology1 个研究点 分布在 1 个国家目标入组 242 人开始时间: 2018年4月12日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 242
- 试验地点
- 1
- 主要终点
- Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1
研究概览
简要总结
A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F-627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
详细描述
Study Stage: Phase III
Study Population: Female patients with breast cancer will be enrolled to receive at least 4 cycles of Epirubicin + Cyclophosphamide (EC) chemotherapy, that is: epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
Study Design: A multi-center, randomized, open-label, active-controlled phase III clinical trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None (Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Willing to sign the informed consent form and able to comply with protocol requirements;
- •18-75 years old;
- •Female postoperative patients with breast cancer who require adjuvant chemotherapy, and are planned to receive at least 4 cycles of EC chemotherapy, namely epirubicin 100 mg/m^2 + cyclophosphamide 600 mg/m^2;
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- •Absolute neutrophil count (ANC) ≥ 2.0 × 10^9/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) ≥ 100 × 10^9/L prior to enrollment;
- •Hepatic and renal functions: Total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, serum creatinine ≤ 1.5 × ULN;
- •Left ventricular ejection fraction > 50%;
- •Women without child-bearing potential, i.e., women who have had menopause for at least 1 year or who have undergone sterilization (bilateral tubal ligation, double oophorectomy or hysterectomy); patients with child-bearing potential should agree to take appropriate contraceptive measures, including condoms, spermicidal condoms, foams, gels, contraceptive barrier, intrauterine devices (IUD), and contraceptives (oral or injection), starting from 1 month before the start of the study until 30 days after the end of the study.
排除标准
- •Radiation therapy within 4 weeks prior to enrollment;
- •Patients with breast cancer who have received neoadjuvant chemotherapy before surgery;
- •Prior bone marrow or stem cell transplant;
- •With other malignant tumors other than breast cancer;
- •Patients who have received a treatment with recombinant human granulocyte colony stimulating factor within 6 weeks prior to randomization;
- •Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by clinical diagnosis, ECG or other approaches;
- •With any disease that may cause splenomegaly;
- •With acute infection, chronic active Hepatitis B within 1 year (unless patients tested negative for HBsAg prior to enrollment), or Hepatitis C;
- •Women in pregnancy or breastfeeding;
- •Known HIV positive or AIDS;
- •With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; TB patients undergoing treatment; or suspected TB evaluated by chest x-ray;
- •With sickle cell anemia;
- •With alcohol or drug abuse that may affect the compliance with the study;
- •With known hypersensitivity to granulocyte colony stimulating factor or excipients;
- •Have received any other investigational drug within 1 month or 5 half-lives of the investigational drugs prior to enrollment (whichever is longer);
- •Patients with diseases or symptoms unsuitable for participating in the trial. For example, the study drugs may compromise the health of the patient or the assessment of adverse events may be affected.
研究组 & 干预措施
F-627
Experimental
F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ± 4 h after the start of chemotherapy
干预措施: F-627 (Drug)
GRAN®
Active Comparator
GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 × 10^9/L] on day 3 of each cycle, i.e., 48 ± 4 h after the start of chemotherapy
干预措施: GRAN® (Drug)
结局指标
主要结局
Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1
时间窗: Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks)
Grade 3 defined as ANC \<1.0×10\^9/L and Grade 4 defined as ANC\<0.5×10\^9/L. According to the study protocol, the outcome measure "Duration of Grade 3 or 4 Neutropenia (days)" applied to all participants with a valid ANC level, rather than those with an ANC level of \< 1.0 × 109/L. The value of 0 represents the participant experienced 0 days with Grade 3 or 4 Neutropenia (days). Whereas exclusion of a participant from the analysis indicates a lack of ANC data of the participant. The mean value was calculated as the sum of the durations (days) of ANC \< 1.0 × 109/L for all participants with valid ANC level (the numerator) divided by the number of participants (the denominator).
次要结局
- Number of Participants With Grade 3 or 4 Neutropenia in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 3 or 4 Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 3 or 4 Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 3 or 4 Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 3 or 4 Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 3 or 4 Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 3 or 4 Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 4 Neutropenia in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 4 Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 4 Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 4 Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 4 Neutropenia in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 4 Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 4 Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration of Grade 4 Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- Overall Duration of Grade 3 or 4 Neutropenia in 4 Cycles(Overall 4, 21-day chemotherapy cycles(average 12 weeks))
- Number of Participants With Grade 2 or Greater Neutropenia in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 2 or Greater Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 2 or Greater Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Number of Participants With Grade 2 or Greater Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration (Days) of Grade 2 or Greater Neutropenia in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration (Days) of Grade 2 or Greater Neutropenia in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration (Days) of Grade 2 or Greater Neutropenia in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Duration (Days) of Grade 2 or Greater Neutropenia in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
- The Absolute Neutrophil Counts (ANC) Nadir From Day 3 to Day 13 of Cycle 1(From day 3 to day 13 of cycle 1 (11 days))
- Number of Participants With Febrile Neutropenia (FN) in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Time (Days) of ANC Nadir Recovers to 2.0 × 10^9/L in Cycle 1(Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks))
- Time (Days) of ANC Nadir Recovers to 2.0 × 10^9/L in Cycle 2(Cycle 2, the second of 4, 21-day chemotherapy cycles (average 3 weeks))
- Time (Days) of ANC Nadir Recovers to 2.0 × 10^9/L in Cycle 3(Cycle 3, the third of 4, 21-day chemotherapy cycles (average 3 weeks))
- Time (Days) of ANC Nadir Recovers to 2.0 × 10^9/L in Cycle 4(Cycle 4, the last of 4, 21-day chemotherapy cycles (average 3 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicNCT02907359Astex Pharmaceuticals, Inc.417
进行中（未招募）
3 期
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceEssential ThrombocythemiaNCT04285086PharmaEssentia174
已完成
3 期
Desidustat in the Treatment of Anemia in CKD on Dialysis PatientsChronic Kidney Disease Stage 5 on DialysisNCT04215120Zydus Lifesciences Limited392
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
已完成
3 期
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerNon-Small Cell Lung CancerNCT03594747BeiGene360